InfuSystem Balances Margin Gains With GE Headwinds

InfuSystem Holdings, Inc. ((INFU)) has held its Q1 earnings call. Read on for the main highlights of the call.

InfuSystem Holdings’ latest earnings call painted a picture of a company in managed transition, balancing solid profitability and balance sheet strength against deliberate revenue headwinds. Management stressed that underlying demand and mix shift toward higher-margin services and wound care remain intact even as GE-related contract changes, ERP costs, and specific product setbacks weigh on near-term GAAP figures.

Pro Forma Growth Masks Headline Revenue Decline

InfuSystem reported Q1 fiscal 2026 net revenue of $33.7 million, down about 3% year over year on a GAAP basis as contract restructuring hit reported numbers. Adjusting for the GE Healthcare deal, however, pro forma revenue actually rose 1.7%, suggesting the core business is still inching forward even as it absorbs a sizable reset.

Adjusted EBITDA Holds Steady With Better Margins

Despite top-line pressure, adjusted EBITDA remained roughly flat at about $6.3 million to $6.4 million for the quarter. The company expanded its adjusted EBITDA margin to 18.9% from 18.2% a year earlier, underscoring tighter cost control and a mix shift toward higher-margin offerings that is helping offset revenue noise.

Gross Profit Rises on Strong Margin Expansion

Gross profit increased by $515,000, or 3%, to reach $19.7 million in Q1, signaling healthier unit economics even in a slower revenue environment. Gross margin climbed about 3.2 percentage points to just over 58%, reflecting better pricing, improved mix, and early benefits from operational initiatives.

Patient Services Show Broad-Based Growth

Patient services net revenue rose $1.3 million, or 6.4% year over year, with oncology revenue up roughly $450,000, a 2.4% gain. Field-based biomedical services, adjusted for the GE contract change, grew nearly $600,000 as the company found new projects and customers to help replace lost volume from the restructured agreement.

Wound Care Emerges as a High-Growth Engine

Wound care continued its rapid ascent, generating $2.1 million of net revenue, about 6% of total sales, and nearly 112% year-over-year growth. Around 60% of that increase came from compression devices, and management added a second supplier of adjustable compression wraps to expand the addressable market and deepen its presence in this fast-growing niche.

ERP Go-Live Marks a Strategic Infrastructure Upgrade

The company successfully went live with its new enterprise resource planning system on March 1, 2026, capping a 20‑month implementation. Management said the integrated platform should enhance productivity, pricing visibility, device utilization, and working capital management over several quarters as they work through stabilization and incremental enhancements.

Device Solutions Margins Improve Despite Volume Hit

Device Solutions gross margin rose to 46.3%, up 3.4 percentage points year over year, even as revenue declined. Device services margins increased more than 7 percentage points, driven by a shift away from the large GE contract toward smaller, higher-margin field service projects that, while lower in volume, add more incremental profit per dollar.

Liquidity Remains Strong With Conservative Leverage

Available liquidity stood at just over $57 million as of March 31, 2026, giving the company ample flexibility for investments and shocks. Net debt ticked up only modestly by $1.1 million, and net debt to adjusted EBITDA stayed low at about 0.56 times, supported by a $20 million revolver draw fixed at 3.8% via swap through 2028.

Share Repurchases Signal Management Confidence

InfuSystem bought back roughly 800,000 common shares during the quarter under its repurchase authorization, a notable move given ongoing operational investments. The buyback activity signals management’s confidence in the intrinsic value of the business and its ability to balance shareholder returns with strategic spending.

GE Contract Restructuring Weighs on GAAP Revenue

GAAP revenue fell around $1.0 million, or 3%, in Q1, largely due to the restructured GE Healthcare biomedical services contract. The revised arrangement reduced quarterly revenue by approximately $1.6 million and is expected to trim about $7.1 million in annual revenue on an ongoing basis, creating a visible drag on reported growth.

Device Solutions Revenue Declines on Contract and Mix

Device Solutions net revenue dropped $2.3 million, or 17%, year over year as the segment absorbed most of the GE restructuring impact. The rest of the decline came from lower rental revenues and equipment sales, including about $432,000 less in rentals and roughly $1.0 million less in equipment sales after a large prior-year customer buyout.

ERP Costs and Disruption Pressure Near-Term Earnings

The ERP rollout brought higher information technology and project expenses, adding about $400,000 to costs in the first quarter. Management acknowledged some initial bugs and stabilization costs and warned that additional post-go-live spending will continue in the near term, keeping SG&A elevated before savings begin to materialize.

Working Capital and Cash Flow Face Temporary Strain

Operating cash flow came in at $970,000, down $817,000 from the prior year, largely due to higher working capital needs tied to the transition period. While net capital expenditures were reduced to $1.3 million from $2.6 million, management indicated that improving cash conversion will be a key focus as ERP processes stabilize.

Labor and Healthcare Costs Add Margin Headwinds

Rising wage and employee healthcare expenses created additional pressure on profitability, partially offsetting margin gains elsewhere. Healthcare benefit costs alone increased by $374,000 in the quarter, and higher wages added to SG&A and gross cost burdens as the company competes for and retains specialized staff.

Chemo Mouthpiece Setback Dampens Pipeline Hopes

The Chemo Mouthpiece product failed to receive expected coding approval early in 2026, representing a setback for one of InfuSystem’s newer initiatives. Management has removed it from guidance and may slow referrals until reimbursement clarity improves, tempering near-term growth expectations for this particular pipeline opportunity.

Guidance Emphasizes Pro Forma Growth and Margin Upside

Looking ahead, InfuSystem reaffirmed pro forma annual revenue growth of 6% to 8% after accounting for the anticipated $7.1 million annual hit from the GE contract restructuring. The company is also targeting an adjusted EBITDA margin in the low- to mid‑20% range, including ERP costs, and expects ERP spend to taper by late Q2 with clearer payoff emerging into year‑end and 2027.

InfuSystem’s earnings call suggested a business deliberately trading headline growth for quality of revenue and higher margins, at least in the short term. Investors will be watching whether wound care momentum, service mix gains, and ERP efficiencies can offset contract headwinds and cost inflation, but the combination of stable profitability, strong liquidity, and active buybacks offers a supportive backdrop.